SAN FRANCISCO, May 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s Management will participate in the following investor conferences during the month of May:
BofA Securities 2025 Health Care Conference
Format: Fireside Chat
Date: Wednesday, May 14, 2025
Time: 1:40 PM ET
2025 RBC Capital Markets Global Healthcare Conference
Format: Fireside Chat
Date: Tuesday, May 20, 2025
Time: 9:30 AM ET
The webcast of the fireside chats will be accessible in the investor section of 89bio’s website. A replay of the webcasts will be available for approximately 30 days following each conference.
About 89bio
89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is in Phase 3 trials for its lead candidate, pegozafermin, for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with advanced fibrosis, including patients with compensated cirrhosis, and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco. For more information, visit www.89bio.com or follow the company on LinkedIn.
Investor Contact:
Annie Chang
89bio, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
PJ Kelleher
LifeSci Advisors, LLC
617-430-7579
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Sheryl Seapy
Real Chemistry
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$9.55 |
| Daily Change: | -0.10 -1.04 |
| Daily Volume: | 367,266 |
| Market Cap: | US$1.120B |
February 27, 2025 February 03, 2025 January 27, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
